Comparison of clinical and biologic variables of all patients according to Id1 expression
| Characteristic . | All patients (n = 237) . | Id1+ (n = 156) . | Id1− (n = 81) . | P . |
|---|---|---|---|---|
| Sex, no. (%) | NS | |||
| Female | 107 (46) | 73 | 34 | |
| Male | 130 (54) | 83 | 47 | |
| Median age, y (range) | 54 (16-80) | 54 | 47 | .009 |
| Median leukocytes, 109/L (range) | 25 (1-284) | 27 | 22 | NS |
| FAB subtypes, no. (%) | NS | |||
| M0 | 10 (4.2) | 7 (70) | 3 | |
| M1 | 58 (24.4) | 39 (67.2) | 19 | |
| M2 | 84 (35.4) | 51 (60.7) | 33 | |
| M4 | 36 (15.2) | 21 (58.3) | 15 | |
| M5 | 43 (18.1) | 32 (74.4) | 11 | |
| M6 | 6 (2.5) | 6 (100) | 0 | |
| Karyotype,* no. (%) | NS | |||
| Good | 23 (9.7) | 14 (60.9) | 9 | |
| Intermediate | 171 (72) | 112 (65.5) | 59 | |
| Normal | 138 (81) | |||
| Other | 33 (19) | |||
| Poor | 38 (16) | 27 (71) | 11 | |
| Not done or not assessable | 5 (2.1) | 3 (60) | 2 | |
| NPM1 mutation status, no. (%) | NS | |||
| NPM1+ | 50 (21.1) | 35 (70) | 15 | |
| NPM1− | 187 (78.9) | 121 (30) | 66 | |
| FLT3/ITD status, no. (%) | .003 | |||
| FLT3/ITD+ | 40 (16.9) | 35 (87.5) | 5 | |
| FLT3/ITD− | 197 (83.1) | 121 (61.4) | 76 | |
| BAALC expression | 1.51 (0.001-16.8), median (range) | 1.67 ± 2.9, mean ± SD | 1.24 ± 2.23, mean ± SD | NS |
| Characteristic . | All patients (n = 237) . | Id1+ (n = 156) . | Id1− (n = 81) . | P . |
|---|---|---|---|---|
| Sex, no. (%) | NS | |||
| Female | 107 (46) | 73 | 34 | |
| Male | 130 (54) | 83 | 47 | |
| Median age, y (range) | 54 (16-80) | 54 | 47 | .009 |
| Median leukocytes, 109/L (range) | 25 (1-284) | 27 | 22 | NS |
| FAB subtypes, no. (%) | NS | |||
| M0 | 10 (4.2) | 7 (70) | 3 | |
| M1 | 58 (24.4) | 39 (67.2) | 19 | |
| M2 | 84 (35.4) | 51 (60.7) | 33 | |
| M4 | 36 (15.2) | 21 (58.3) | 15 | |
| M5 | 43 (18.1) | 32 (74.4) | 11 | |
| M6 | 6 (2.5) | 6 (100) | 0 | |
| Karyotype,* no. (%) | NS | |||
| Good | 23 (9.7) | 14 (60.9) | 9 | |
| Intermediate | 171 (72) | 112 (65.5) | 59 | |
| Normal | 138 (81) | |||
| Other | 33 (19) | |||
| Poor | 38 (16) | 27 (71) | 11 | |
| Not done or not assessable | 5 (2.1) | 3 (60) | 2 | |
| NPM1 mutation status, no. (%) | NS | |||
| NPM1+ | 50 (21.1) | 35 (70) | 15 | |
| NPM1− | 187 (78.9) | 121 (30) | 66 | |
| FLT3/ITD status, no. (%) | .003 | |||
| FLT3/ITD+ | 40 (16.9) | 35 (87.5) | 5 | |
| FLT3/ITD− | 197 (83.1) | 121 (61.4) | 76 | |
| BAALC expression | 1.51 (0.001-16.8), median (range) | 1.67 ± 2.9, mean ± SD | 1.24 ± 2.23, mean ± SD | NS |
NS indicates not significant.
Good karyotypes included t(8;21) and inv(16); poor karyotypes included 3q26rearangements, t(6;9), del(7)/−7, del(5)/−5 and 3 or more than 3 abnormalities.